Polyrizon Files Patent for Trap & Target™ Drug Delivery
Ticker: PLRZ · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, intellectual property, drug delivery
TL;DR
Polyrizon files patent for its T&T intranasal drug delivery platform, protecting innovation.
AI Summary
Polyrizon Ltd. announced on January 30, 2025, that it has filed a divisional patent application for its Trap & Target™ (T&T) intranasal drug delivery platform. This filing is part of the company's ongoing efforts to protect its intellectual property related to this innovative technology.
Why It Matters
This patent filing aims to secure intellectual property for Polyrizon's novel drug delivery system, potentially enhancing its value and market position in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This is a routine patent filing announcement, which typically carries low immediate risk.
Key Numbers
- 001-42375 — SEC File Number (Polyrizon Ltd.'s SEC filing identifier)
- 333-284410 — Registration Statement File Number (Incorporated by reference in the 6-K filing)
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- Trap & Target™ (T&T) (technology) — Intranasal Drug Delivery Platform
- January 30, 2025 (date) — Filing Date
- Form S-8 (File No. 333-284410) (document) — Incorporated Registration Statement
FAQ
What is the primary purpose of the patent application filed by Polyrizon Ltd.?
The patent application is for Polyrizon's innovative Trap & Target™ (T&T) intranasal drug delivery platform, aimed at protecting its intellectual property.
When was the press release announcing the patent filing issued?
The press release was issued on January 30, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 5 Ha-Tidhar Street Raanana, 4366507, Israel.
Which SEC form is Polyrizon Ltd. required to file annual reports under?
Polyrizon Ltd. files annual reports under cover of Form 20-F.
What specific exhibit is incorporated by reference into the Form 6-K?
Exhibit 99.1, which contains the Registrant's press release issued on January 30, 2025, is incorporated by reference.
Filing Stats: 268 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-01-30 06:06:12
Filing Documents
- ea0229228-6k_polyrizon.htm (6-K) — 10KB
- ea022922802ex99-1_polyrizon.htm (EX-99.1) — 16KB
- 0001213900-25-008058.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: January 30, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2